Heinrich Haas

TL;DR: It is shown that DCs can be targeted precisely and effectively in vivo using intravenously administered RNA-lipoplexes (RNA-LPX) based on well-known lipid carriers by optimally adjusting net charge, without the need for functionalization of particles with molecular ligands.

TL;DR: Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4 + and CD8 + T-cell immunity.

TL;DR: In this paper, the authors compared synthetic mRNA and sa-RNA expressing influenza virus hemagglutinin, and concluded that saRNA is a promising platform for vaccines against viral diseases.

TL;DR: In this article, pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration are described. But they are not suitable for use in immunotherapy.

TL;DR: The steps for translating novel RNA nanomedicines into clinical trials are described, which include a therapeutic vaccine for intravenous administration based on a fixed set of four RNA lipoplex drug products, each encoding for one shared tumor antigen.